| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | -0.1 | 0.008 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | 0.083 | 0.008 |
| mRNA | MS-275 | CTRPv2 | pan-cancer | AAC | 0.085 | 0.009 |
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | 0.088 | 0.009 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.009 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.14 | 0.01 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.085 | 0.01 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.11 | 0.01 |
| mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | -0.094 | 0.01 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | 0.079 | 0.01 |